Loading organizations...
Key people at Quantum SI.
Quantum-Si develops a benchtop platform for single-molecule protein analysis, aiming to make this technology broadly accessible. The company's system utilizes real-time, kinetic-based detection to bypass conventional multi-step processes. This approach provides researchers with dynamic and functional protein insights at unparalleled resolution, enhancing understanding of complex biological systems.
Dr. Jonathan M. Rothberg, an accomplished inventor, founded Quantum-Si in 2013. His foundational insight was to democratize protein sequencing, extending its reach beyond specialized facilities to the broader proteomics and multiomics community. Dr. Rothberg's vision centered on simplifying access to crucial protein information.
Quantum-Si's solutions serve life science researchers, enabling them to analyze proteins with greater efficiency and depth. The company's overarching mission is to accelerate proteomic discoveries by making protein analysis simpler, faster, and more informative. This commitment drives progress toward improving human health and understanding disease at a fundamental level.
Key people at Quantum SI.
Quantum-Si is a biotechnology company founded in 2013 that develops next-generation protein sequencing (NGPS™) platforms to revolutionize proteomics by enabling single-molecule, single-amino-acid resolution analysis.[1][2] Their flagship products, Platinum and Platinum Pro, are advanced benchtop sequencers that provide real-time kinetic insights, detect proteoforms and post-translational modifications, and support applications in biomarker discovery, disease mechanisms, antibody characterization, and drug development—all with simplified workflows requiring less than three hours of hands-on time and no dedicated lab space.[1] These tools serve academic researchers, biopharma companies, and diagnostics developers by addressing limitations of traditional methods like Edman degradation and mass spectrometry, unlocking proteome-scale insights to accelerate scientific research and therapeutic advancements.[1][2]
The company integrates biology, chemistry, and AI to make protein sequencing accessible, positioning it as a pioneer in the post-genomic era and driving growth through accessible proteomics for variant detection and protein identification.[1]
Quantum-Si was founded in 2013 with a mission to pioneer protein sequencing in the post-genomic era, emerging from the need to extend DNA sequencing breakthroughs into proteomics.[1] Headquartered in Branford, Connecticut, the company was established to tackle the challenges of digitizing proteomic research using a novel sequencing chip that enables next-generation protein sequencing™.[2] Key early focus centered on developing single-molecule resolution technology powered by kinetic signatures, which simplified workflows compared to legacy methods and gained traction through innovations like the Platinum and Platinum Pro sequencers.[1][2] This evolution reflects a pivotal shift toward scalable, AI-enhanced tools that minimize reliance on antibodies and mass spectrometry, marking foundational moments in making proteomics as routine as genomics.[1]
Quantum-Si's technology stands out in proteomics through these key advantages:
Quantum-Si rides the proteomics revolution, a trend shifting from genomics to proteins as the next frontier in precision medicine, where understanding proteoforms and modifications unlocks drug discovery and diagnostics unattainable via DNA sequencing alone.[1][2] Timing is ideal amid surging demand for proteome-scale data in biopharma, fueled by AI advancements in biology and post-pandemic emphasis on rapid therapeutics—market forces like aging populations and chronic disease burdens amplify this, with proteomics projected to grow as a multi-billion-dollar field.[2] By democratizing single-molecule sequencing, Quantum-Si influences the ecosystem, empowering researchers to bypass traditional bottlenecks, accelerate antibody therapeutics, and integrate proteomics into AI-driven drug pipelines, fostering broader innovations in personalized medicine.[1]
Quantum-Si is poised to expand its NGPS™ leadership with platform enhancements, potentially scaling to high-throughput applications and deeper AI integrations for real-time clinical insights. Trends like AI-biology convergence and proteogenomics will shape its path, amplifying impact in oncology biomarkers and novel therapeutics. Its influence may evolve from research enabler to diagnostics powerhouse, solidifying proteomics as genomics' essential counterpart and transforming how we decode life's functional machinery.[1][2]
